Deucravacitinib Improves Psoriasis Symptoms and Signs Diary Domain Scores in Patients With Moderate to Severe Plaque Psoriasis: Results From the Phase 3 POETYK PSO-1 and POETYK PSO-2 Studies

Main Article Content

April Armstrong
Bruce Strober
Kenneth Gordon
Joe Zhuo
Brandon Becker
Renata Kisa
John Throup
Jonghyeon Kim
Kim Papp


Deucravacitinib, psoriasis, POETYK PSO trial, diary domain score




1. Burke JR et al. Sci Transl Med 2019;11:1-16.

2. Armstrong A et al. Presented at the Annual Meeting of the American Academy of Dermatology; April 23-25, 2021.

3. Feldman SR et al. J Dermatol Trans Surg 2016;20:19-26.

4. Mathias SD et al. J Dermatol Treat 2016;27:322-327.

5. Komiya E et al. Int J Mol Sci 2020;21:8406.

Similar Articles

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 > >>